Pharmaceutical Company Representatives
This page lists 304 references in the Main Healthy Skepticism Library relevant to Pharmaceutical Company Representatives.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL6736
Saunders C.
Drug reps can be a useful source of information if used the right way
Australian Doctor 2006 Sep 6
http://www.australiandoctor.com.au/news/9a/0c043e9a.asp
HSL6000
Musacchio R, Hunkler R
More Than a Game of Keep Away
Pharmaceutical Executive 2006 Jul 7
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=323311
HSL5930
Schneider JA, Arora V, Kasza K, Van Harrison R, Humphrey H.
Residents' Perceptions Over Time of Pharmaceutical Industry Interactions and Gifts and the Effect of an Educational Intervention.
Acad Med 2006 Jul 01;81(7):595-602
Link to source with long URL
HSL6882
Flewell MN.
Pharmaceutical sales reps: value beyond samples.
Adv Nurse Pract 2006 Jul 01;14(7):18
HSL6984
Standridge JB.
Of doctor conventions and drug companies.
Fam Med 2006 Jul-Aug 01;38(7):518-20
http://www.stfm.org/fmhub/fm2006/July/John518.pdf
HSL6134
Roner L.
Defining pharma’s marketing future Part I – You are here
Eyeforpharma 2006 Jun 30
http://www.eyeforpharma.com/index.asp?nli=o&g-p&nld=7/3/2006&news=51595
HSL5814
Adair R.
Hidden costs of free samples
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):367-371
http://www.ama-assn.org/ama/pub/category/16251.html
HSL5815
Sierles FS.
The gift-giving influence
Virtual Mentor: Ethics Journal of the American Medical Association 2006 Jun 1;8(6):372-376
http://www.ama-assn.org/ama/pub/category/16252.html
HSL6101
Ohbayashi H.
[Results of a survey questionnaire concerning smoking conditions in 54 major Japanese pharmaceutical companies and among their employees].
Nihon Kokyuki Gakkai Zasshi 2006 May 01;44(5):374-83
HSL5585
Larson K, Levy J, Rome MG, Matte TD, Silver LD, Frieden TR.
Public health detailing: a strategy to improve the delivery of clinical preventive services in New York City.
Public Health Rep 2006 May-Jun;121(3):228-34
HSL4517
Hill K.
Free Lunch?
The American Journal of Psychiatry 2006 Apr(163):569-570
http://ajp.psychiatryonline.org/cgi/content/full/163/4/569
HSL5123
Doran E, Kerridge I, McNeill P, Henry D.
Empirical uncertainty and moral contest: a qualitative analysis of the relationship between medical specialists and the pharmaceutical industry in Australia.
Soc Sci Med 2006 Mar;62(6):1510-9
Link to source with long URL
HSL5500
Guglielmo WJ.
Scheduling drug reps online.
Med Econ 2006 Feb 17;83(4):49-50,
HSL6399
Wen LS, McCoy C.
Response to 'Interactions between pharmaceutical representatives and doctors in training: a thematic review'.
J Gen Intern Med 2006 Jan 01;21(1):103
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2005.00271_4.x
HSL5302
Brekke KR, Kuhn M.
Direct to consumer advertising in pharmaceutical markets.
J Health Econ 2006 Jan;25(1):102-30
Link to source with long URL
HSL6735
Morgan MA, Dana J, Loewenstein G, Zinberg S, .
Interactions of doctors with the pharmaceutical industry
J Med Ethics 2006;32:559-563
http://jme.bmjjournals.com/cgi/content/full/32/10/559
HSL4035
Huang F, Et AL.
The Association of Pharmaceutical Company Promotional Spending With Resident Physician Prescribing Behavior
Academic Psychiatry 2005 Dec 1(29):500-501
http://ap.psychiatryonline.org/cgi/content/full/29/5/500
HSL5271
Muijrers PE, Grol RP, Sijbrandij J, Janknegt R, Knottnerus JA.
Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives.
Fam Pract 2005 Dec;22(6):624-30
Link to source with long URL
HSL5327
Fonzo-Christe C, Herrmann F, Bonnabry P.
Quality assessment of the visits of pharmaceutical company representatives to hospital pharmacists.
Swiss Med Wkly 2005 Nov 19;135(45-46):666-73
Link to source with long URL
HSL5998
Grant DC, Iserson KV.
Who's buying lunch: are gifts to surgeons from industry bad for patients?
Thorac Surg Clin 2005 Nov 01;15(4):533-42
HSL4223
Verdoux H, Cougnard A, Grolleau S, Begaud B.
Impact of visits from pharmaceutical company representatives on antipsychotic prescription in primary care.
Schizophr Res 2005 Sep 1;77(1):107-9
http://linkinghub.elsevier.com/retrieve/pii/S0920-9964(05)00066-6
HSL2665
Roner L
Resident physicians not enamored with drug reps
eyeforpharma Briefing 2005 Aug 17(151)
http://www.eyeforpharma.com/index.asp?nli=o&g-p&nld=8/17/2005&news=47334
HSL1985
Zipkin DA, Steinman MA.
Interactions Between Pharmaceutical Representatives and Doctors in Training: A thematic review.
J Gen Intern Med 2005 Jun 13;20(8):777-86
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1525-1497.2005.0134.x
HSL2134
Dubovsky SL.
Who is teaching psychopharmacology? Who should be teaching psychopharmacology?
Academic Psychiatry 29:155-161, June 2005 2005 Jun 01;29:155-161
http://ap.psychiatryonline.org/cgi/content/full/29/2/155
HSL1882
Brownlee S, Lenzer J.
Spin Doctored: How drug companies keep tabs on physicians.
Slate Magazine 2005 May 31
http://slate.msn.com/id/2119712/
HSL1858
Behar D, Schaller JL.
Letter to the Editor: Drug rep visits actually improve care for patients
American Medical Association News 2005-2005 May-May 23-30
HSL1859
Edwards J.
Where There's A Pill, There's A Way
Brandweek.com 2005 May 16
HSL1774
Kaufman M.
Merck CEO Resigns as Drug Probe Continues
The Washington Post 2005 May 6
HSL1775
Appleby J.
Merck's marketing of Vioxx called misleading
USA TODAY 2005 May 6
http://www.usatoday.com/printedition/money/20050506/vioxx06.art.htm
HSL1881
Berliner N.
Customized Detailing through Physician Categorization
2005 Apr
HSL1888
Wofford JL, Ohl CA.
Teaching appropriate interactions with pharmaceutical company representatives: the impact of an innovative workshop on student attitudes.
BMC Med Educ 2005 Feb 8;5(1):5
http://www.biomedcentral.com/content/pdf/1472-6920-5-5.pdf
HSL5316
Granja M.
[Dangerous liaisons--physicians and pharmaceutical sales representatives].
Acta Med Port 2005 Jan-Feb;18(1):61-8
http://www.actamedicaportuguesa.com/pdf/2005-18/1/061-068.pdf
HSL5317
Brody H.
The company we keep: why physicians should refuse to see pharmaceutical representatives.
Ann Fam Med 2005 Jan-Feb;3(1):82-5
http://www.annfammed.org/cgi/content/full/3/1/82
HSL1887
Randall ML, Rosenbaum JR, Rohrbaugh RM, Rosenheck RA.
Attitudes and behaviors of psychiatry residents toward pharmaceutical representatives before and after an educational intervention.
Acad Psychiatry 2005 Spr;29(1):33-9
http://ap.psychiatryonline.org/cgi/content/abstract/29/1/33
HSL4187
Manchanda P, Honka E.
The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review.
Yale J Health Policy Law Ethics 2005 Sum;5(2):785-822
HSL5983
Campo K, De Staebel O, Gijsbrechts E, van Waterschoot W.
Physicians' decision process for drug prescription and the impact of pharmaceutical marketing mix instruments.
Health Mark Q 2005;22(4):73-107
HSL5985
Parker RS, Pettijohn CE.
Pharmaceutical drug marketing strategies and tactics: a comparative analysis of attitudes held by pharmaceutical representatives and physicians.
Health Mark Q 2005;22(4):27-43
HSL2143
Bellin M, McCarthy S, Drevlow L, Pierach C.
Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school.
Acad Med. 2004 Nov;79(11):1041-5. 2004 Nov 01;79(11):1041-5
http://www.academicmedicine.org/cgi/content/full/79/11/1041
HSL1347
Wazana A, Granich A, Primeau F, Bhanji NH, Jalbert M.
Using the literature in developing McGill's guidelines for interactions between residents and the pharmaceutical industry.
Acad Med 2004 Nov;79(11):1033-40
http://www.academicmedicine.org/cgi/content/full/79/11/1033
HSL2094
Agrawal S, Saluja I, Kaczorowski J.
A prospective before-and-after trial of an educational intervention about pharmaceutical marketing.
Acad Med 2004 Nov;79(11):1046-50
http://www.academicmedicine.org/cgi/content/full/79/11/1046
HSL2208
O'Donnell MJ, Molloy DW, Smith SD, Dubois S, Russo RM.
The self-perceived role and educational needs of pharmaceutical representatives: a survey.
Educ Health (Abingdon) 2004 Nov;17(3):339-45
HSL2821
Donohue JM, Berndt ER.
Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants
Journal of Public Policy & Marketing 2004 Fall;23(2):115–127
Link to source with long URL
HSL5092
Oldani MJ.
Thick prescriptions: toward an interpretation of pharmaceutical sales practices.
Med Anthropol Q 2004 Sep;18(3):325-56
HSL2109
Reist D, Vandecreek L.
The pharmaceutical industry's use of gifts and educational events to influence prescription practices: Ethical dilemmas and implications for psychologists
Professional psychology-research and practice 2004 Aug;35(4):329-335
HSL1351
Watkins RS, Kimberly J Jr.
What residents don't know about physician-pharmaceutical industry interactions.
Acad Med 2004 May;79(5):432-7
http://www.academicmedicine.org/cgi/content/full/79/5/432
HSL1987
Greene JA.
Attention to 'details': etiquette and the pharmaceutical salesman in postwar American.
Soc Stud Sci 2004 Apr;34(2):271-92
HSL5609
Kramer TA.
A plea for biased information.
MedGenMed 2004 Feb 10;6(1):31
Link to source with long URL
HSL2127
Tengilimoglu D, Korkmaz S, Akinci F, Parsons AL.
Managerial implications of medical sales representative perceptions of job duties, job qualifications, and other performance-related issues.
Health Mark Q 2004;22(2):3-26
HSL2151
Keim S, Perina DG; CORD Board of Directors.
Council of Emergency Medicine Residency Directors position on interactions between emergency medicine residencies and the pharmaceutical industry.
Acad Emerg Med 2004 Jan;11(1):78
http://www.aemj.org/cgi/content/full/11/1/78
HSL2152
Keim SM, Mays MZ, Grant D.
Interactions between emergency medicine programs and the pharmaceutical industry.
Acad Emerg Med 2004 Jan;11(1):19-26
http://www.aemj.org/cgi/content/full/11/1/19
HSL4242
Tengilimoglu D, Kisa A, Ekiyor A.
The pharmaceutical sales rep/physician relationship in Turkey: ethical issues in an international context.
Health Mark Q 2004;22(1):21-39
HSL4243
Tengilimoglu D, Korkmaz S, Akinci F, Parsons AL.
Managerial implications of medical sales representative perceptions of job duties, job qualifications, and other performance-related issues.
Health Mark Q 2004;22(2):3-26
HSL1475
Baena Diez JM, Lopez Mompo C, Lopez Gosp D, Martinez Martinez JL, Ellacuria Torres A, Fuentes Rodriguez S.
[Good morning, Mr. Representative. Anything new to tell us about? Analysis of the pharmacological products introduced by the drugs industry into a health district]
Aten Primaria 2003 Dec 01;32(10):557-61
Link to source with long URL
HSL2712
Mizik M, Jacobsen R
Are Physicians Easy Marks?: Quantifying the effects of Detailing and Sampling on New Prescriptions.
Unpublished 2003 Oct
Nil
HSL1433
Harris G, Mayho G, Page L.
Occupational health issues affecting the pharmaceutical sales force.
Occup Med (Lond) 2003 Sep;53(6):378-83
http://occmed.oupjournals.org/cgi/reprint/53/6/378
HSL2501
Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R.
Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study.
BMJ 2003 May 31;326(7400):1178-9
http://bmj.bmjjournals.com/cgi/content/full/326/7400/1178
HSL1786
Prosser H, Walley T.
Understanding why GPs see pharmaceutical representatives: a qualitative interview study.
Br J Gen Pract 2003 Apr;53(489):305-11
Link to source with long URL
HSL2441
Prosser H, Almond S, Walley T.
Influences on GPs' decision to prescribe new drugs-the importance of who says what.
Fam Pract 2003 Feb;20(1):61-8
http://fampra.oxfordjournals.org/cgi/content/full/20/1/61
HSL2500
Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R.
Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey.
Qual Saf Health Care 2003 Feb;12(1):29-34
http://qhc.bmjjournals.com/cgi/content/full/12/1/29
HSL1440
Floyd T.
Conflict of interest courtesy of drug reps...
BMJ 2003 Jan 5;325(7377):1375
http://bmj.com/cgi/eletters/325/7377/1375
HSL1450
Desmet C.
Pharmaceutical firms' generosity and physicians: legal aspects in Belgium.
Med Law 2003;22(3):473-87
Link to source with long URL
HSL1485
Wirth M, Scherer D.
Patient's perceptions of doctors' relationships with pharmaceutical companies
Healthy Skepticism International News 2002 Nov;20(11)
www.healthyskepticism.org
HSL2499
Caamano F, Figueiras A , Gestal-Otero JJ.
Influence of commercial information on prescription quantity in primary care.
Eur J Public Health 2002 Sep;12(3):187-91
Link to source with long URL
HSL2245
Wall LL, Brown D.
Pharmaceutical sales representatives and the doctor/patient relationship.
Obstet Gynecol 2002 Sep;100(3):594-9
http://www.greenjournal.org/cgi/content/full/100/3/594
HSL2891
Charatan F.
Doctor sues company over unethical marketing.
BMJ 2002 May 25;324(7348):1234
http://bmj.com/cgi/content/full/324/7348/1234/b
HSL2155
Romano M.
Student rally Med school attendees write ethics code on drug firms.
Mod Healthc 2002 May 13;32(19):24,
HSL2896
Brody H.
A matter of influence: Changing times call for changing policies on the prescence of drug company reps in residency programs
Health Affairs (Millwood). 2002 Mar-Apr;21(2):232-234
http://www.healthaffairs.org/freecontent/s28.htm
HSL2156
Glazer JL.
Pharmaceutical representatives and resident physicians.
JAMA 2002 Feb 20;287(7):844
http://jama.ama-assn.org/cgi/content/full/287/7/844
HSL119
Wilkes MS, Hoffman JR.
An innovative approach to educating medical students about pharmaceutical promotion.
Acad Med 2001 Dec;76(12):1271-1277
http://www.academicmedicine.org/cgi/content/full/76/12/1271
HSL2510
McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS.
Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior.
JAMA 2001 Oct 24-31;286(16):1994-9
http://jama.ama-assn.org/cgi/content/full/286/16/1994
HSL2720
Schwartz TL, Kuhles DJ 2nd, Wade M, Masand PS.
Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits.
Ann Clin Psychiatry 2001 Sep;13(3):159-62
Link to source with long URL
HSL129
Jones MI, Greenfield SM, Bradley CP.
Prescribing new drugs: qualitative study of influences on consultants and general practitioners
BMJ 2001;323:378-384
http://bmj.bmjjournals.com/cgi/content/full/323/7309/378
HSL121
Stout E.
Doctoring sales
Sales & Marketing Management 2001 May:52-60
Nil
HSL2380
Dieperink ME, Drogemuller L.
Industry-sponsored grand rounds and prescribing behavior.
JAMA 2001 Mar 21;285(11):1443-4
http://jama.ama-assn.org/cgi/content/full/285/11/1443
HSL130
Gönül FF, Carter F, Petrova E, Srinivasan K.
Promotion of prescription drugs and its impact on physicians' choice behavior
Journal of Marketing 2001;65:79-90
Nil
HSL2979
Canadian Medical Association
CMA Policy: Physicians and the pharmaceutical industry (Update 2001)
2001
Link to source with long URL
HSL360
Backer EL, Lebsack JA, Van Tonder RJ, Crabtree BF.
The value of pharmaceutical representative visits and medication samples in community-based family practices.
J Fam Pract 2000 Sep;49(9):811-6
Nil
HSL3050
Maestri E, Furlani G, Suzzi F, Campomori A, Formoso G, Magrini N.
So much time for so little: Italy's pharmaceutical industry and doctors' information needs.
BMJ 2000 Jan 1;320(7226):55-6
http://bmj.com/cgi/content/full/320/7226/55
HSL349
Guldal D, Semin S.
The influences of drug companies' advertising programs on physicians
Int J Health Serv 2000;30(3):585-95
Nil
HSL2220
Gaedeke RM, Tootelian DH, Sanders EE.
Value of services provided by pharmaceutical companies: perceptions of physicians and pharmaceutical sales representatives.
Health Mark Q 1999;17(1):23-31
HSL2692
Dolovich L, Levine M, Tarajos R, Duku E.
Promoting optimal antibiotic therapy for otitis media using commercially sponsored evidence-based detailing: A prospective controlled trial.
Drug Information Journal 1999;33(4):1067-1077
Link to source with long URL
HSL540
Kamat VR, Nichter M.
Pharmacies, self-medication and pharmaceutical marketing in Bombay, India.
Soc Sci Med 1998 Sep;47(6):779-94
Link to source with long URL
HSL531
Lexchin J.
Residents and pharmaceutical representatives.
Can Fam Physician 1998 Jul;44:1448
Nil
HSL517
Roughead EE, Harvey KJ, Gilbert AL.
Commercial detailing techniques used by pharmaceutical representatives to influence prescribing.
Aust N Z J Med 1998 Jun;28(3):306-10
Nil
HSL538
Kelcher S, Brownoff R, Meadows LM.
Structured approach to pharmaceutical representatives. Family medicine residency program
Can Fam Physician 1998 May;44:1053-60
Nil
HSL519
Roughead EE, Gilbert AL, Harvey KJ.
Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners?
Int J Health Serv 1998;28(2):269-79
Nil
HSL2221
Creyer EH, Hrsistodoulakis I.
Marketing pharmaceutical products to physicians. Sales reps influence physicians' impressions of the industry
Mark Health Serv. 1998 Sum;18(2):34-8
HSL708
Lewin-Fetter V.
Pharmaceutical representatives.
Lancet 1997 Dec 13;350(9093):1784
HSL2218
Lexchin J.
What information do physicians receive from pharmaceutical representatives?
Can Fam Physician 1997 May;43:941-5
Nil
HSL721
Herman AA, McCarthy BJ, Bakewell JM, Ward RH, Mueller BA, Maconochie NE, Read AW, Zadka P, Skjaerven R.
Data linkage methods used in maternally-linked birth and infant death surveillance data sets from the United States (Georgia, Missouri, Utah and Washington State), Israel, Norway, Scotland and Western Australia.
Paediatr Perinat Epidemiol 1997 Jan;11
http://www.bmj.com/cgi/content/full/315/7106/480
HSL677
Shear NH, Black F, Lexchin J.
Physician-detailer interaction—II.
Can J Clin Pharmacol 1997;4(1):10
Nil
HSL681
Sanders HD.
Physician-detailer interaction—I.
Can J Clin Pharmacol 1997;4(1):9
Nil
HSL712
Jeffries JJ.
Physician-detailer interaction—II.
Can J Clin Pharmacol 1997;43(1):10
HSL756
Strang D, Gagnon M, Molloy W, Bedard M, Darzins P, Etchells E, Davidson W.
National survey on the attitudes of Canadian physicians towards drug-detailing by pharmaceutical representatives.
Ann R Coll Physicians Surg Can 1996 Dec;29(8):474-8
HSL761
Sergeant MD, Hodgetts PG, Godwin M, Walker DM, McHenry P.
Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario.
CMAJ 1996 Nov 1;155(9):1243-
HSL2385
Stryer D, Bero LA.
Characteristics of materials distributed by drug companies. An evaluation of appropriateness.
J Gen Intern Med 1996 Oct;11(10):575-83
Nil
HSL760
Shaughnessy AF, Slawson DC.
Pharmaceutical representatives.
BMJ 1996 Jun 15;312(7045):1494
http://www.bmj.com/cgi/content/full/312/7045/1494
HSL802
Caudill TS, Johnson MS, Rich EC, McKinney WP.
Physicians, pharmaceutical sales representatives, and the cost of prescribing.
Arch Fam Med 1996 Apr;5(4):201-
HSL768
Peppin JF.
Pharmaceutical sales representatives and physicians: ethical considerations of a relationship.
J Med Philos 1996 Feb;21(1):83-99
HSL2723
Spingarn RW, Berlin JA, Strom BL.
When pharmaceutical manufacturers' employees present grand rounds, what do residents remember?
Acad Med 1996 Jan;71(1):86-8
Link to source with long URL
HSL759
Shear NH, Black F, Lexchin J.
Examining the physician-detailer interaction
Can J Clin Pharmacol 1996;3(4):175-179
HSL784
Jewesson P, Herar S.
Activities of pharmaceutical industry representatives at a major teaching hospital.
Can J Hosp Pharm 1996;49:256-260
HSL809
Aldir RE, Jarjoura D, Phinney M, Poordad F, Gutierrez R, Marnejon T, Greifenstein E, Lappin J, Whittier FC.
Practicing and resident physician’s views on pharmaceutical companies.
J Contin Educ Health Prof 1996;16:25-32
HSL822
Shaughnessy AF, Slawson DC, Bennett JH.
Teaching information mastery: evaluating information provided by pharmaceutical representatives.
Fam Med 1995 Oct;27(9):581-5
Nil
HSL844
Hodges B.
Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.
CMAJ 1995 Sep 1;153(5):553-9
HSL1720
Arkinstall WW.
Interaction between physicians and the pharmaceutical industry.
CMAJ 1995 Aug 15;153(4):398-9
HSL816
Tong KL, Lien CY.
Do pharmaceutical representatives misuse their drug samples?
Can Fam Physician 1995 Aug;41:1363-6
HSL811
Ziegler MG, Lew P, Singer BC.
The accuracy of drug information from pharmaceutical sales representatives.
JAMA 1995 Apr 26;273(16):1296-8
Nil
HSL857
Colby WD.
Guidelines for interaction with the pharmaceutical industry.
CMAJ 1995 Apr 1;152(7):1040-2
HSL2453
Branthwaite A, Downing T.
Marketing to doctors - the human factor.
Scrip Magazine 1995:32-5
Nil
HSL813
Williams PA, Cockerill R, Lowy FH.
The physician as prescriber: relations between knowledge about prescription drugs, encounters with patients and the pharmaceutical industry, and prescription volume
Health and Canadian Society 1995;3:135-166
HSL848
Guyatt G.
L’enseignement de la médeicne et l’ industrie pharmaceutique
CMAJ 1995;152:1039-1040
HSL855
Dasta JF, Visconti JA, Hawksworth K.
The adoption of clarithromycin by university-based physicians during its first year of commercial availability
J Pharm Mark Manage 1995;9(3):3-20
HSL1719
Bardelay D, Bécel B.
Visits from medical representatives: fine principles, poor practice
Prescrire International 1995;4(18):120-122
Nil
HSL1721
Andaleeb SS, Tallman RF.
Physician attitudes toward pharmaceutical sales representatives.
Health Care Manage Rev 1995 Sum;20(3):68-76
HSL2689
Chren MM, Landefeld CS.
Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary.
JAMA 1994 Mar 2;271(9):684-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed
HSL2498
Berings D, Blondeel L, Habraken H.
The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice.
Eur J Clin Pharmacol 1994;46(6):501-5
Link to source with long URL
HSL6283
Physicians and the pharmaceutical industry (update 1994)
Canadian Medical Association Journal 1994;150:256A-256C
HSL6289
Chren M-M, Landefeld CS.
Pharmaceutical promotion and physician requests to hospital formularies
JAMA 1994;272:355
HSL6467
Danby FW.
Interacting with the pharmaceutical industry
Canadian Medical Association Journal 1994;151:732
HSL6477
Gardner L.
Professional organizations and healthcare industry support: ethical conflict. Commentary
Cambridge Quarterly of Healthcare Ethics 1994;3:247-253
HSL6478
Gesensway D.
Dealing with the new breed of detailers: the drug industry wants to be your ‘essential medical educator’
ACP Observer 1994;14(8):8-9
HSL6599
Guyatt G.
Interacting with the pharmaceutical industry
Canadian Medical Association Journal 1994;151:732
HSL2522
Lexchin J.
Interactions between physicians and the pharmaceutical industry: what does the literature say?
CMAJ 1993 Nov 15;149(10):1401-7
Link to source with long URL
HSL5785
Reeder M, Dougherty J, White LJ.
Pharmaceutical representatives and emergency medicine residents: a national survey.
Ann Emerg Med 1993 Oct;22(10):1593-6
Link to source with long URL
HSL5696
Lexchin J.
Physicians and drug companies interact.
Can Fam Physician 1993 Sep 01;39:1881-2
HSL5535
Howie JG.
Breaking down drug company barriers
BMJ 1993;307:384
HSL5537
Huston P.
Doctors want more industry-sponsored meetings
Medical Marketing & Media 1993;28(3):48-50, 52-53
HSL5705
Michalko K, Gibbs B.
Pharmaceutical representative committee
Canadian Journal of Hospital Pharmacy 1993;46:84
HSL4985
Africa survey shows pharma information valued
Health Horizons 1992 Oct(17):12-13
HSL4988
Chetley A.
Promoting health or pushing drugs?
HAI News 1992 Oct(67):1-2, 10-12
HSL2190
Brotzman GL, Mark DH.
Policy recommendations for pharmaceutical representative-resident interactions.
Fam Med 1992 Aug;24(6):431-2
HSL2182
Lichstein PR, Turner RC, O'Brien K.
Impact of pharmaceutical company representatives on internal medicine residency programs. A survey of residency program directors
Arch Intern Med. 1992 May;152(5):1009-13.
HSL4969
Schofield I.
Prescrire—challenging marketing and promotional practices in France
Scrip Magazine 1992 Apr(3):8-9
www.pjbpubs.co.uk/scrip/scrhome.html www.pjbpubs.co.uk/scrip/scrhome.html
HSL2183
Brotzman GL, Mark DH.
Policies regulating the activities of pharmaceutical representatives in residency programs.
J Fam Pract 1992 Jan;34(1):54-7
HSL2184
Bucci KK, Frey KA.
Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives.
J Fam Pract 1992 Jan;34(1):49-52
HSL2690
Cleary JD.
Impact of pharmaceutical sales representatives on physician antibiotic prescribing.
J Pharm Technol 1992 Jan-Feb;8(1):27-9
Link to source with long URL
HSL4854
Margolis LH.
Physicians' interactions with pharmaceutical companies [2nd of two letters]
Pediatrics 1992;90:281
HSL4871
Nixon AJ.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146(328-329)
HSL4889
Paterson AH.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146:328
HSL4896
Robinson LA.
Physicians and the pharmaceutical industry
Canadian Medical Association Journal 1992;147:5822-583
HSL4912
Stallings S.
From printing press to pharmaceutical representative: a social history of drug advertising and promotion
Journal of Drug Issues 1992;22:205-219
HSL4913
Swanson RW.
Three cheers for CME?
Canadian Medical Association Journal 1992;146:1519
HSL4937
Woollard RF.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146:332
HSL4646
Chan J, Einarson T.
Drug detailing in the hospital: background for policy development
Canadian Journal of Hospital Pharmacy 1991;44:161-166
HSL4663
Harvey K, Mansfield P.
Drug promotion: the critical approach
Australian Prescriber 1991;14(1):34-35
HSL4701
Rovers JP.
The doctor’s, the druggist’s, and the detail rep’s dance: who leads, who follows?
Canadian Family Physician 1991;37:100-104
HSL4708
Smith NC, Quelch JA.
Pharmaceutical marketing practices in the Third World
Journal of Business Research 1991;23:113-126
HSL4712
Taylor RJ, Bond CM.
Change in the established prescribing habits of general practitioners: an analysis of initial prescriptions in general practice
British Journal of General Practice 1991;41:244-248
HSL2193
McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC.
Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives.
JAMA 1990 Oct 3;264(13):1693-7
HSL4633
Wilson GJ.
Training sales reps 1990s style
Medical Marketing & Media 1990 Oct;25(10):16-18, 20, 23-24, 26, 28
HSL4631
Saade C, Huff-rousselle M.
Pakistan: should ORS be marketed like other drugs?
Dialogue on Diarrhoea 1990 Sep(42):6
HSL2194
Lurie N, Rich EC, Simpson DE, Meyer J, Schiedermayer DL, Goodman JL, McKinney WP.
Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff.
J Gen Intern Med 1990 May-Jun;5(3):240-3
HSL4500
Ahmad SR, Bhutta ZA.
A survey of pediatric prescribing and dispensing in Karachi
Journal of the Pakistan Medical Association 1990;40:126-130
HSL4521
Chetley A.
A healthy business? World health and the pharmaceutical industry
Zed Books 1990
Link to source with long URL
HSL4523
Cockerill R.
Report on the 1989 survey of the dispensing practices and attitudes toward prescription drugs of Ontario pharmacists
1990
HSL4546
Lexchin J.
Disinformation from pharmaceutical company representatives
Canadian Medical Association Journal 1990;143:370
HSL4566
Pye J.
“Disinformation” from pharmaceutical company representatives
Canadian Medical Association Journal 1990;142:1178
HSL4574
Roeg N.
The other drug trade
Adbusters 1990;1(4):80-87
www.adbusters.org/adbusters/
HSL4604
Williams AP, Cockerill R.
Report on the 1989 survey of the prescribing experiences and attitudes toward prescription drugs of Ontario physicians
1990
HSL4485
Greenwood J.
Prescribing and salesmanship
HAI News 1989 Aug(48):1-2, 11
HSL4467
Prescriptions for profit
1989 Mar 28
HSL2075
Ferguson RP.
Training the resident to meet the detail men.
JAMA 1989 Feb 17;261(7):992-3
HSL4114
Further proposals on medicines
Lancet 1989;2:752-753
HSL4410
Fogel ML.
Survey of pharmaceutical promotion in a family medicine training program
Canadian Family Physician 1989;35:1603-1605
HSL4412
Franklin K.
The pharmaceutical tango
New Physician 1989;38(5):24-28
HSL4414
Greenwood J.
Pharmaceutical representatives and the prescribing of drugs by family doctors
1989
HSL4419
The effect of journal advertising on market shares of new prescriptions
1989
HSL4437
Martin JH.
The ethics of physician-pharmaceutical company relationships
Canadian Medical Association Journal 1989;140:10
HSL4446
Rachlis M, Kushner C.
Second opinion: what’s wrong with Canada’s health-care system and how to fix it
1989
HSL4112
Brief submitted to the Pharmaceutical Inquiry of Ontario
1988 Nov 28:10
HSL4107
Rosenthal E.
Madison Avenue medicine
Discover 1988 Oct;9(10):34-36
HSL4068
Shaughnessy AF.
Drug promotion in a family medicine training center.
JAMA 1988 Aug 19;260(7):926
HSL4088
Healthcare communications and pharmaceutical promotion
Health Horizons 1988 May(4):16-17
HSL4002
[No authors listed] Related Articles, Links Improving medical education in therapeutics.
Health and Public Policy Committee, American College of Physicians.
Ann Intern Med 1988 Jan;108(1):145-7
HSL3996
Ferguson A.
Commercial pharmaceutical medicine and medicalization: a case study from El Salvador
1988
HSL4004
Hemminki E.
Commercial information on drugs: confusing the physician?
Journal of Drug Issues 1988;18:245-257
HSL4006
Hopley PJ, Rich AJ.
Pharmaceutical company representatives - an activity analysis
Pharmaceutical Journal 1988;241:R21-22
HSL4014
Lefkowitz D.
Rap sheet on reps: the doctor will see you now
Pharmaceutical Executive 1988;8(6)
HSL4016
Lexchin J.
Introducing a new drug: an objection
Canadian Family Physician 1988;34:1009-1010
HSL4017
Lexchin J.
Pharmaceutical promotion in New Zealand.
Community Health Stud 1988;12(3):264-72
HSL4028
Osiobe SA.
Physicians’ and pharmacists’ drug information sources in Nigeria
Drug Information Journal 1988;22:553-563
HSL4029
Palmer WH, Ross DL.
Introducing a new drug: a response
Canadian Family Physician 1988;34:1010
HSL4031
Peay MY, Peay ER.
The role of commercial sources in the adoption of a new drug.
Soc Sci Med 1988;26(12):1183-9
Link to source with long URL
HSL4032
Pitt L, Nel D.
Pharmaceutical promotion tools—their relative importance
European Journal of Marketing 1988;22:7-14
HSL4072
Tan M.
Dying for drugs: pill power and politics in the Philippines
1988
HSL3967
Crane VS, Jefferson KK, Morgan R.
Rethinking pharmaceutical industry relationships.
Am J Hosp Pharm 1987 Aug;44(8):1884-6
HSL3890
Hull FM, Marshall T.
Sources of information about new drugs and attitudes towards drug prescribing: an international study of differences between primary care physicians.
Fam Pract 1987 Jun;4(2):123-8
HSL3922
Thomas J 3rd.
National survey of hospital policies on pharmaceutical sales representatives' activities.
Am J Hosp Pharm 1987 Jun;44(6):1334-40
HSL3887
Hay DR.
Drug promotion.
N Z Med J 1987 Apr 8;100(821):223
HSL3913
Shelley JH.
Relationships between physicians and the pharmaceutical industry: London Royal College of Physicians 1986.
Br J Clin Pharmacol 1987 Mar;23(3):257-8
HSL3871
Chotiner G.
Response
Journal of the American Academy of Dermatology 1987;17:866
HSL3877
Freeman JW, Kaatz B.
The physician and the pharmaceutical detail man: an ethical analysis
Journal of Medical Humanities and Bioethics 1987;8:34-39
HSL3883
Greenhalgh T.
Drug prescription and self-medication in India: an exploratory survey.
Soc Sci Med 1987;25(3):307-18
HSL3903
Lexchin J.
Pharmaceutical promotion in Canada: convince them or confuse them.
Int J Health Serv 1987;17(1):77-89
HSL3908
Palmer WH, Ross DL.
Introducing a new drug into your practice
Canadian Family Physician 1987;33:2529-2533
HSL3930
Wolffers I.
Drug information and sale practices in some pharmacies of Colombo, Sri Lanka.
Soc Sci Med 1987;25(3):319-21
HSL3822
Smith R.
Doctors and the drug industry: too close for comfort.
Br Med J (Clin Res Ed) 1986 Oct 11;293(6552):905-6
HSL3851
Greenhalgh T.
Beneath cosmetic reforms
HAI News 1986 Oct
HSL3848
Lexchin J.
Good health?
New Outlook 1986 Sep-Oct:24-26, 28-31
HSL3755
Bayer UK Ltd suspended over actions by representatives
Pharmaceutical Journal 1986;237:821-822
HSL3784
Greenhalgh T.
Marketing drugs in the Third World
Lancet 1986;2:222
HSL3816
Perkin RL.
The pharmaceutical industry
Canadian Family Physician 1986;32:2013
HSL3818
Roseman EP.
Checking the scorecard
Medical Marketing & Media 1986;21(10):40, 42, 44
HSL3832
Woods D.
PMAC to spend almost $1 million annually to reach “stakeholders”
Canadian Medical Association Journal 1986;134:1387, 1389
HSL3752
Teplitsky B.
A 30-year trend: what chief pharmacists think about detailers.
Pharm Times 1985 Nov;51(11):83-92
HSL3729
Osiobe SA.
Sources of information for biomedical decision-making.
Methods Inf Med 1985 Oct;24(4):225-9
HSL3716
Jefferis JE.
The pharmaceutical industry and academic medicine: opportunities for physician collaboration.
Circulation 1985 Aug;72(2)
HSL3717
Kaplan NM.
Educating physicians in the use of pharmaceuticals.
Circulation 1985 Aug;72(2)
HSL3728
Murphy PA.
One drug company's sales techniques.
N Engl J Med 1985 Jul 25;313(4):270
HSL3732
Smith R.
Doctors and the drug industry in Sweden.
Br Med J (Clin Res Ed) 1985 Feb 9;290(6466):448-50
HSL3708
Benseman J.
The great paper waste: the use of unsolicited medical literature by general practitioners
New Zealand Family Physician 1985;12:96-98
HSL3712
Dasco CC.
A physician/medical industrial ethos
American Journal of Medicine 1985;79:675
HSL3731
Putnam RW, Fox RD, Mazmanian PE.
Report to Pharmaceutical Manufacturers Association of Canada: an analysis of drug prescribing changes by physicians
1985
HSL3691
Gabe L.
You can reach the hard-to-see MD!
Medical Marketing & Media 1984 Oct;19:63, 66, 68-69
HSL3690
Joubert PH, Skene D.
Attitudes of private medical practitioners towards package inserts and other drug information sources.
S Afr Med J 1984 Aug 25;66(8):306-7
HSL3666
Powell SH, Stempien MJ, Vogenberg FR.
Hospital-based training for pharmaceutical manufacturers' representatives.
Am J Hosp Pharm 1984 Jan;41(1):70,
HSL3641
Lexchin J.
The real pushers: a critical analysis of the Canadian drug industry
1984
HSL3648
Parboosingh J, Lockyer J, McDougall G, Chugh U.
How physicians make changes in their clinical practice: a study of physicians’ perception of factors that facilitate this process
Annals of the Royal College of Physicians and Surgeons of Canada 1984;17:429-435
HSL3572
Barker C.
The Mozambique pharmaceutical policy.
Lancet 1983 Oct 1;2(8353):780-2
HSL3607
Phillips DJ, Smith JE.
Hospital-based training for pharmaceutical manufacturers' representatives.
Am J Hosp Pharm 1983 Oct;40(10):1661-3
HSL3602
Willcox GS, Mahoney CD, Jeffrey LP.
Monitoring the hospital activities of medical service representatives.
Am J Hosp Pharm 1983 Jun;40(6):989-91
HSL3599
Getting good value from drug reps.
Drug Ther Bull. 1983 Feb 25;21(4):13-5
HSL3597
Massengill R Jr, Verghese A, Robert T.
Course for drug representatives.
J Med Educ 1983 Jan;58(1):86
HSL3586
Klein T.
Detailing and other forms of promotion
1983:400-417
HSL3587
Lumbard J.
Foremost problem? Medical service representatives
Hospital Pharmacy 1983;18:134
HSL3593
Quraeshi ZA, Luqmani M, Malhotra N.
Brands or generics: the dilemma of pharmaceutical marketing in a developing country.
J Health Care Mark 1983 Fal;3(4):27-37
HSL3550
O'Malley K, O'Hanrahan M.
Drug promotion and the doctor.
Br J Clin Pharmacol 1982 Nov;14(5):661-4
HSL3534
Bainbridge CV, D'Ambrosio GG, Petrick RJ, Weiss EM.
Pharmaceutical manufacturer's responses to drug information inquiries.
Am J Hosp Pharm 1982 Sep;39(9):1532-4
HSL3542
Hatton RC, Doering PL, Frias JL.
Physicians' sources of information about teratogenic effects of drugs.
Drug Inf J 1982 Jul-Sep;16(3):148-53
HSL3562
McGhan W, Seery S, Hill B, Koda R.
Hospital pharmacists' attitudes towards medical services representatives: a comparison of directors, staff, and clinical pharmacists.
Hosp Formul 1982 Jul;17(7):957-61
HSL3546
Melrose D.
Bitter pills: medicines and the Third World poor
1982
HSL3533
Publicity and the public’s ‘right to know’
New Zealand Pharmacy 1982;2(6):19, 22
HSL3538
Cooperstock R, Hill J.
The effects of tranquillization: benzodiazepine use in Canada
Health and Welfare Canada 1982
HSL3544
McMillan JH.
Information about medicines
New Zealand Medical Journal 1982;95:674-675
HSL3547
Melville A, Johnson C.
Cured to death: the effects of prescription drugs
1982
HSL3529
Richter R.
Pesticides and pills: for export only Part two: pharmaceuticals
1981 Oct 24
HSL3518
Oppenheim GL, Erickson SH, Ashworth C.
The family physician's knowledge of the cost of prescribed drugs.
J Fam Pract 1981 Jun;12(6):1027-30
HSL3497
Blum R, Kreitman K.
Factors affecting individual use of medicines
1981:122-185
HSL3512
Hymans R.
NZ Institute of Medical Representatives
New Zealand Medical Journal 1981;94:11
HSL3517
Meadows R.
Communicating new drug information—the medium is the message
Drug Information Journal 1981;15:11-15
HSL3523
Tennent RB.
Trade representatives
New Zealand Medical Journal 1981;93:314
HSL3481
Strickland-Hodge B, Jeqson MH.
Usage of information sources by general practitioners.
J R Soc Med 1980 Dec;73(12):857-62
HSL3463
Epstein P, Yudkin JS.
Agranulocytosis in Mozambique due to amidopyrine, a drug withdrawn in the west.
Lancet 1980 Aug 2;2(8188):254-5
HSL3464
Gambrill J, Bridges-Webb C.
Use of sources of therapeutic and prescribing information by general practitioners.
Aust Fam Physician 1980 Jul;9(7):482-4
HSL3476
Manning PR, Denson TA.
How internists learned about cimetidine.
Ann Intern Med 1980 May;92(5):690-2
HSL3461
Colville P.
New material for medical representatives pharmacology course
Pharmaceutical Journal of New Zealand 1980;42(6):5-7
HSL3470
Hurd P.
The potential value of unfavorable information
Medical Marketing & Media 1980;15(5):42-44, 46
HSL3471
Hutchinson G.
Prescribing drugs—generic vs trade names
McGill Medical Journal 1980;46(1):2-6
HSL3477
Rheinstein P, Baum CS.
Labeling effectiveness and the health environment
1980;6:275-287
HSL3478
Rivin AU.
"Ethical" drugs.
Pharos Alpha Omega Alpha Honor Med Soc 1980 Spr;43(2):9-10
HSL3456
Kleinman G.
The physician’s drug adoption process re: product risk
Medical Marketing & Media 1979 Nov;14:46, 48-50
HSL3451
Dukes MN.
Identifying the medical consultants of pharmaceutical companies.
Lancet 1979 Sep 29;2(8144):696
HSL3424
Fitzgerald FT.
Detail men in white coats.
N Engl J Med 1979 Sep 20;301(12):668
HSL3450
Burley DM.
Identifying the medical consultants of pharmaceutical companies.
Lancet 1979 Aug 18;2(8138):354
HSL3449
Lunde PK, Herxheimer A.
Identifying the medical consultants of pharmaceutical companies.
Lancet 1979 Jul 28;2(8135):197
HSL3412
Binns TB, Smith A.
Medical representatives.
Br Med J 1979 Apr 28;1(6171):1134-5
HSL3427
Hughes R, Brewin R.
The tranquilizing of America: pill popping and the American way of life
1979
HSL3395
Kalb CC.
Psychological motivations in physician prescribing habits.
Med Mark Media 1978 Oct;13(10):43-5,
HSL3405
Talley CR.
Hospitals defend formulary decisions against industry attacks.
Am J Hosp Pharm 1978 Sep;35(9):1154-5
HSL3403
Roustan PT.
The pharmaceutical manufacturers representative.
Drug Inf J 1978 Jan-Mar;12(1):15-9
HSL3391
Harrell GD, Lindsay CM.
Pharmaceutical marketing
1978:69-90
HSL3397
Lall S, Bibile S.
The political economy of controlling transnationals: the pharmaceutical industry in Sri Lanka, 1972-1976.
Int J Health Serv 1978;8(2):299-328
HSL3409
Eastman M.
The day the detail man talked
American Pharmacy 1978;18(11):592
HSL3411
Bell W.
Accredited pharmaceutical manufacturers representatives
Canadian Medical Association Journal 1978;120:1327
HSL3351
Da Sylva NP.
Drug information sources for the practicing physician.
Drug Inf J 1977 Oct-Dec;11(4):235-7
HSL3367
Marchand CR.
Physician attitudes toward sources of drug information.
Drug Inf J 1977 Oct-Dec;11(4):225-6
HSL3360
Holland AE.
Representatives and advertisements as sources of information.
Postgrad Med J 1977 Sep;53(623):559-61
HSL3368
Martin RW.
Drug costs.
N Z Med J 1977 Aug 24;86(594):202
HSL3386
Mergener M.
Detailmen: Their pharmaceutical knowledge and continuing education
Medical Marketing & Media 1977 Aug;12(8):26, 28-31
HSL3361
Holmes JD.
Drug costs.
N Z Med J 1977 Jul 27;86(592):108-9
HSL3383
Cocking C.
The abuse of prescription drugs
Weekend Magazine 1977 Jun 18:16-19
HSL3349
Carpenter GE.
New Zealand Institute of Medical Representatives.
N Z Med J 1977 May 11;85(587):395-6
HSL3357
Hemminki E.
Content analysis of drug-detailing by pharmaceutical representatives.
Med Educ 1977 May;11(3):210-5
HSL3358
Hemminki E, Pesonen T.
The function of drug company representatives.
Scand J Soc Med 1977;5(3):105-14
HSL3379
MacLayton DW, Garner DD.
Physicians' evaluation of an ideal detailman's attributes
Medical Marketing & Media 1977;12(2):22, 24-26, 28-30
HSL3299
A critical look at the drug industry: how profits distort medicine
1976:31
HSL3302
Eaton G, Parish P.
Sources of drug information used by general practitioners.
J R Coll Gen Pract 1976;26
HSL3303
Hargraves R.
Introduction
Journal of Drug Issues 1976;6:1-5
HSL3312
Nelson G.
Advertising and the national health
Journal of Drug Issues 1976;6:28-33
HSL3316
Silverman M, Lee PR.
Pills, profits & politics
University of California Press 1976
HSL3331
Brooke P.
Promotional parameters: a preliminary examination of promotional expenditures
Journal of Drug Issues 1976;6(1):21-27
HSL3275
Mailloud J.
The drug companies role in the supply of information
1975 May 30-31
HSL3247
Moser RH.
Editorial: The continuing search: FDA drug information survey.
JAMA 1974 Sep 2;229(10):1336-8
HSL3267
Siegelman S.
How pharmacists rate detailmen
American Druggist 1974 Aug 1;170(3):19, 56-62
HSL3255
Gould D.
Can we handle modern drugs?
New Scientist 1974 May 23;62(899):460-1
HSL3256
Greenberg D.
Cleaning up the drug trade
New Scientist 1974 May 23;62:491
HSL3236
Bowes R.
The industry as pusher
Journal of Drug Issues 1974;4:238-242
HSL3237
Cooperstock R.
Some factors involved in the increased prescribing of psychotropic drugs
Alcoholism and Drug Addiction Research Foundation of Ontario 1974
HSL3242
Hess SW.
Communicating with physicians
Journal of Advertising Research 1974;14(1):13-18
HSL3246
Miller RR.
Prescribing habits of physicians: a review of studies on prescribing of drugs. Parts VII-Viii
Drug Intelligence and Clinical Pharmacy 1974;8:81-91
HSL3249
Nelson G.
New laws are needed to regulate the drug industry
Journal of Drug Issues 1974;4:243-248
HSL3253
Wolfe SM.
Scientific evaluations dispute advertising claims
Journal of Drug Issues 1974;4:249-253
HSL3265
Simmons H.
The role of the Food and Drug Administration in regulating drug advertising
Journal of Drug Issues 1974;4:291-296
HSL3230
Worthen DB.
Prescribing influences: an overview.
Br J Med Educ 1973 Jun;7(2):109-17
HSL3224
Miller RR.
Prescribing habits of physicians: a review of studies on prescribing of drugs. Parts I-III
Drug Intelligence and Clinical Pharmacy 1973;7:492-500
HSL3225
Miller RR.
Prescribing habits of physicians: a review of studies on prescribing of drugs. Parts IV-VI
Drug Intelligence and Clinical Pharmacy 1973;7:557-564
HSL3229
Wallace JD.
An APMR? Now what would that be?
Canadian Medical Association Journal 1973;108:1302
HSL2503
Becker MH, Stolley PD, Lasagna L, McEvilla JD, Sloane LM.
Differential education concerning therapeutics and resultant physician prescribing patterns.
J Med Educ 1972 Feb;47(2):118-27
Link to source with long URL
HSL3218
Torrance GM.
The influence of the drug industry in Canada’s health system
1972 Jan:48
HSL3221
Stolley PD, Becker MH, Lasagna L, McEvilla JD, Sloane LM.
The relationship between physician characteristics and prescribing appropriateness.
Med Care 1972 Jan-Feb;10(1):17-28
HSL3173
The peculiar success of Chloromycetin
Consumer Reports 1970 Oct;35(10):616-619
HSL3174
Hammel RW.
Physician evaluation of pharmaceutical manufacturers and their detailmen: How it effects their prescribing
Medical Marketing & Media 1970 Oct;5(10):7-8, 10, 12, 14
HSL3135
Canadian doctors more sceptical of drug promotion than U.S. counterparts—report
Canadian Medical Association Journal 1970;102:884, 886